-
US House faces test on sweeping Russia sanctions bill
-
IR-MED and Dice Technologies Announce collaboration to Evaluate and Advance Pressure-Injury Prevention Platform in Japan
-
British PM says to make 'difficult decisions' as inflation rises
-
Watts, Pitt, Cruz to light up Spain's top film festival
-
Global fuel price demos: a round-up
-
Toogood Gold's Table Mountain Sits in the Shadow of a Nevada Gold Rush
-
Leverate Launches MCP for Traders to Connect AI Assistants With Trading Platforms
-
MEXC July–August Security Report: 38.66M USDT in Risk Funds Intercepted, Futures Insurance Fund Hits 792M USDT
-
MEXC Launches $1M "Discover Your Wall Street DNA" Campaign to Help Traders Find Their Market Fit
-
Emporio Armani names Dario Vitale new creative director
-
Stocks edge higher ahead of US Fed rate call
-
EU to ban social media for under 13s, curb access until 15
-
BASIS.pro Expands On-Chain Infrastructure with XDC Network Partnership and Zypher DAO as Auto Earn Goes Live
-
Wildfires push endangered Sumatran elephants to brink: Indonesian NGO
-
Pickle-flavoured tart? AI inspires Japan's convenience stores
-
Bank of Japan set to raise rates under pressure from inflation, US
-
EU chief hosts Canada's Carney in push to 'deepen' alliance
-
EU chief to unveil social media, gaming curbs for under-15s
-
Meta chief pushes back on AI slowdown calls
-
'Resident Evil' film brings video game's ethos to the big screen
-
US Fed to deliver rate decision with markets betting on hike
-
i-payout Expands U.S. Money Transmitter Licensing Footprint and Advances European EMI Strategy
-
Sanders, Bannon warn of AI dangers in rare US left-right alignment
-
US Senate crypto bill collapses amid partisan deadlock
-
Empty benches as schools reopen in Venezuela's quake-hit Guaira
-
OpenAI, Anthropic and Google are working to create an AI standards body
-
Tiny English village holds 'independence' vote over asylum seeker housing
-
Protesting shepherds, farmers clash with Romanian police
-
US Treasury chief says to meet Chinese counterpart at weekend
-
Foundation Lets Ledger Users Switch to Open Source Without Starting Over
-
BingX Evolves into a Multi-Asset Trading Platform, Connecting Users to Global Opportunities
-
EU to propose curbing social media, online games for under 15s
-
International Trading Institute Expands Professional Trader Development Beyond the Master’s in Trading
-
FX Junction Reaches 40,600 Members and 26 Million Trades
-
Lake Energy Secures $80 Million for U.S. Renewable Energy Expansion
-
'We unleashed the beast': the world's fears and hopes about AI
-
Stocks drop, oil climbs and Treasury yields hit 19-year high
-
Hospitality leaders ask Burnham to halve VAT amid rising costs
-
SkySail Strategies Outperforms Wall Street's 30-Year Risk Standard With Proprietary AI Inference Model
-
Worcestershire invited to nominate groups for 2027 King’s volunteer award
-
Just add fish: Scientists pursue more rice, less disease in Senegal paddies
-
Berlin's run-down public spaces at heart of election campaign
-
Belgium completes outer structure of offshore energy island
-
'Widow's Bay' and 'The Pitt' win big at Emmy Awards
-
China retail sales growth weakens further in August
-
Most markets drop as oil extends gains ahead of expected US rate hike
-
In Kashmir, lake weeds mix with traditional art
-
Sri Lanka's famed beach shack battles demolition
-
'Widow's Bay' and 'The Pitt' take key Emmy awards
-
Vserv targets ₹1,000 crore revenue by 2030 through AI expansion
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
J.Bondarev--CPN